Novo Nordisk completes patient enrollment in A1chieve study for type 2 diabetes management

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

Spanning 28 countries across 4 continents and involving more than 3300 physicians, A1chieve(R) is set to be the world's largest observational study in insulin therapy.

Approximately 70 percent of the world's 285 million people with diabetes are living in these 28 emerging countries where there is a rising need and interest to look at differences in physician decisions in the management of diabetes.

"Multinational observational studies like A1chieve(R) provide valuable insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances," said Philip Home, Professor of Diabetes Medicine at Newcastle University England and Chair of the A1chieve(R) Global Advisory Board.

In order to mimic the natural secretion of insulin in the body, commercially available insulin preparations are used in different ways (regimens) based on an individual's need and prevailing local practices. However it is important to evaluate these different regimens in a real life setting.

"Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes" added Professor Home.

Jesper H0iland, Senior Vice President, Novo Nordisk Region International Operations A/S said "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

The results of this multinational study will be available in 2011.

Source:

NOVO NORDISK

Advertisement

Comments

  1. alija haseta alija haseta Bosnia and Herzegovina says:

    Podržavam studiju koja če definitivnobiti dobar pokazatelj kontrole dijabetesa ,te u zemlji u razvoju a to je Bosna i Hercegovina koja se ne pominje nigdje  če biti od velikog značaja jel ljudi koji prate vaš rad koriste i vaša iskustva,i dostignuča. Samo mi iz Humanitarnog udruženja DIABETES  Sarajevo Bosna i Hercegovina imamo zamolbu da i nas imate u vidu u nekoj studiji,jel i ovdje ima ljudi oboljeli od dijabetesa,a svi su potošači Novo Nordisk inzulina a ta kompanija nas ne uvrštava ni na kartu bilo kojeg značajnog događaja.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Report suggests possible remission of type 2 diabetes through weight loss